RecruitingNot ApplicableNCT06682936

Feasibility of Ambulatory Talc. Pleurodesis

Can Talc Pleurodesis for Malignant Pleural Effusion be Performed on an Ambulatory Basis


Sponsor

David Rollins

Enrollment

15 participants

Start Date

Jan 10, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life. The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Malignant pleural effusion
  • Life expectancy >30 days
  • WHO PS 1-2 (3 if due to dyspnoea)

Exclusion Criteria2

  • Previous failed pleurodesis (on affected side)
  • Known non-expansile lung

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREambulatory chest drain and talc pleurodesis

a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis


Locations(1)

North Tees and Hartlepool NHS foundation trust

Stockton-on-Tees, County Durham, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06682936


Related Trials